GB2162061A — Controlled time release therapeutic composition having means for counteracting overdosage
Assigned to Individual · Expires 1986-01-29 · 40y expired
What this patent protects
The composition contains a therapeutic agent and an emetic or a purgative. The quantity of emetic or purgative is adjusted according to the quantity of therapeutic agent such that the emetic or purgative causes emesis or purgation of the therapeutic agent when excessive amounts o…
USPTO Abstract
The composition contains a therapeutic agent and an emetic or a purgative. The quantity of emetic or purgative is adjusted according to the quantity of therapeutic agent such that the emetic or purgative causes emesis or purgation of the therapeutic agent when excessive amounts of the agent are ingested. The availability of the therapeutic agent for absorption or local action is delayed, using a time delay material e.g. an enteric coating, beyond the time required for emesis or purgation so that the composition will be expelled from the body before the therapeutic agent begins to act in the event that excessive amounts of the composition are ingested.
Drugs covered by this patent
- OxyContin (oxycodone) · Purdue Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.